Collagenase‐Coated Polymeric Drug/siRNA Nanoparticles Overcome ECM and Regulate Metabolic Reprogramming of Fibroblasts for Alleviating Pulmonary Fibrosis
Small · 2026-09 · 22 (49)
DOI: 10.1002/smll.202512872 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 03.07.2026. Verfasst von Shihong Cheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stomatology, Shanghai Eighth People's Hospital, Xuhui Branch of Shanghai Sixth People's Hospital, Shanghai, China. Hauptthemen laut MEDLINE: RNA, Small Interfering, Nanoparticles, Fibroblasts, Pulmonary Fibrosis. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Shenzhen Municipal Science and Technology Innovation Council, Shenzhen Key Laboratory of Neural Cell Reprogramming and Drug Research.
Abstract (Originalsprache)
Pulmonary fibrosis (PF) is a progressive lung disease characterized by abnormal extracellular matrix (ECM) accumulation, leading to respiratory dysfunction and eventual respiratory failure. The pathogenesis involves fibroblast migration, proliferation, and activation via the CXCL12/CXCR4 axis, resulting in collagen deposition and ECM accumulation. Additionally, this axis drives epithelial‐mesenchymal transition (EMT) and angiogenesis. Under hypoxic conditions induced by ECM accumulation, pyruvate dehydrogenase kinase 1 (PDK1) further promotes fibroblasts differentiation into myofibroblasts by enhancing metabolic reprogramming towards glycolysis. To target these multifaceted pathological processes, a collagenase‐coated polymeric drug/siRNA delivery system is engineered. This system comprises PPLFazo, hypoxia‐responsive polymer of plerixafor (CXCR4 inhibitor), loaded with PDK1 siRNA (siPDK1) and encapsulated by collagenase‐conjugated polyglutamic acid. Upon inhalation, the collagenase degrades ECM barrier, facilitating PPLFazo/siPDK1 recognition and endocytosis by fibroblasts. In the hypoxic microenvironment, both plerixafor monomers and siPDK1 are released, exerting their targeted therapeutic effects. Pharmacodynamic evaluations in murine PF models demonstrated that PPLFazo/siPDK1@G‐CLG reduced myofibroblast accumulation, decreased collagen deposition, and attenuated abnormal fibrotic tissue growth in the lungs. These findings collectively indicate substantial amelioration of PF. By simultaneously targeting multiple pathological pathways, this system offers a novel strategy to combat this challenging disease, potentially improving patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Stomatology, Shanghai Eighth People's Hospital, Xuhui Branch of Shanghai Sixth People's Hospital, Shanghai, China.
- School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen, China.
ORCID-Profile: Shihong Cheng, Yang Liu
Förderung
- National Natural Science Foundation of China
- Shenzhen Municipal Science and Technology Innovation Council
- Shenzhen Key Laboratory of Neural Cell Reprogramming and Drug Research
- Pearl River S and T Nova Program of Guangzhou Municipality
Zitieren
APA
Cheng, S., Luo, P., Chi, H., Zhang, Y., Li, C., Wang, X., Liu, Y., & Li, G. (2026). Collagenase‐Coated Polymeric Drug/siRNA Nanoparticles Overcome ECM and Regulate Metabolic Reprogramming of Fibroblasts for Alleviating Pulmonary Fibrosis. Small, 22(49). https://doi.org/10.1002/smll.202512872
Vancouver
Cheng S, Luo P, Chi H, Zhang Y, Li C, Wang X, et al. Collagenase‐Coated Polymeric Drug/siRNA Nanoparticles Overcome ECM and Regulate Metabolic Reprogramming of Fibroblasts for Alleviating Pulmonary Fibrosis. Small. 2026;22(49). doi:10.1002/smll.202512872
BibTeX
@article{Cheng2026,
author = {Cheng, Shihong and Luo, Pingping and Chi, Huirong and Zhang, Yiqiu and Li, Chujie and Wang, Xiyan and Liu, Yang and Li, Guolin},
title = {Collagenase‐Coated Polymeric Drug/siRNA Nanoparticles Overcome ECM and Regulate Metabolic Reprogramming of Fibroblasts for Alleviating Pulmonary Fibrosis},
journal = {Small},
year = {2026},
volume = {22},
number = {49},
doi = {10.1002/smll.202512872}
}
EUVIMED